Documentation scienceplus.abes.fr version Bêta

À propos de : Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry        

AttributsValeurs
type
Is Part Of
Subject
Title
  • Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry
has manifestation of work
related by
Abstract
  • Objective. To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement. Methods. Patients with pSS and PNS involvement who were included in the French AIR registry were analysed. Results. 17 patients (age 60 years (44-78 years); 14 were female) were analysed. Neurological improvement was noted in 11 patients (65%) at 3 months. Rankin scale decreased from 3 (1-5) to 2 (1-5), 2 (1-5) and 2 (1-6) after 3, 6 and 9 months (p=0.02). European Sjögren's Syndrome Disease Activity Index decreased from 18 (10-44) to 11 (5-20), 11 (5-29) and 12 (5-30) after 3, 6 and 9 months (p<0.05). RTX was effective in neurological involvement in 9/10 patients with vasculitis or cryoglobulinaemia (90%) (group 1) at 3 months and in 2/7 cases (29%) without cryoglobulinaemia and vasculitis (p=0.03). Rankin and European Sjögren's Syndrome Disease Activity Index scales decreased significantly in group 1. Conclusion. RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.
article type
publisher identifier
  • annrheumdis-2011-200086
is part of this journal
PubMed ID
  • 21926185



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata